Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 24;8:737257. doi: 10.3389/fcvm.2021.737257

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Tanacli, Doeblin, Götze, Zieschang, Faragli, Stehning, Korosoglou, Erley, Weiss, Berger, Pröpper, Steinbeis, Kühne, Seidel, Geisel, Cannon Walter-Rittel, Stawowy, Witzenrath, Klingel, Van Linthout, Pieske, Tschöpe and Kelle.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Lake Louise Criteria (LLC) and Functional Impairment in patients with COVID-19 and patients with Myocarditis. (A) Comparison of the CMR LLC and endomyocardial biopsy (EMB) findings. Three out of 32 (9%) patients with COVID-19 and all 22 (100%) of the patients with myocarditis have positive LLC, (B) from the patients in which endomyocardial biopsy (EMB) was available: none of the patients with COVID-19 and 13 (87%) out of 15 patients with myocarditis with available EMB had histological findings in keeping with this diagnosis, 1 (10%) of the patients with COVID-19, and 2 (13%) of the patients with myocarditis have positive LLC but negative EMC diagnostic criteria. (C) tables with numeric values for CMR LLC (upper rows) and Endomyocardial Biopsy Analyses (lower rows) (D) spidernet representation of myocardial inflammation, injury, pericardial involvement, LV, and RV dysfunctions in all COVID-19 (blue polygons) and all Myocarditis (red polygons) patients, (E) (baseline), (F) (follow-up)–spidernet representations of myocardial inflammation, injury, pericardial involvement, LV, and RV dysfunctions in patients with COVID-19 (blue polygons) and Myocarditis (red polygons) with an available follow-up scan.